Navigation Links
Pharmaceutical Water Markets, the Economic Crunch Creates New Opportunities in Southern and Eastern Europe
Date:12/8/2008

LONDON, Dec. 8 /PRNewswire/ -- High Purity Water is a critical ingredient in the manufacturing process of life saving drugs. The continuing demand for high quality water (HQW) is the single biggest driver for the growth of the water treatment systems market segment in the pharmaceutical sector. Frost & Sullivan's European Environment Research Analyst, Karthikeyan Ravikumar, foresees "that the water and wastewater management market in the European pharmaceutical industry has exciting opportunities to offer particularly in the water treatment segment with the overall market experiencing high growth rates".

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

With Europe as the second largest pharmaceutical manufacturing markets around it has emerged as a very lucrative high value opportunity to stake holders in the water industry. Some of the leading players have made significant investments on research and development as well as positioning themselves as providers of specialist solutions for the pharmaceutical sectors. These investments are channelled to enhance innovative water and wastewater treatment solutions, test and improve existing technologies to meet the current and expected changes to the European Pharmacopoeia's water standards.

The European pharmaceutical market is expected to showcase an annual growth rate of around 8-10 percent in the coming years and this is expected to reflect in a steady increase in the need for effective and efficient water as well as wastewater treatment technologies and services.

Furthermore, the current economic situation may open new and interesting opportunities in Southern and Eastern Europe. Karthikeyan Ravikumar reports that "with the economic slowdown triggered from the United States of America spreading to other regions of the globe, the pharmaceutical industries in Europe may take a cautious stand of wait and watch policy". This cautious stand could have an impact on the water and wastewater management needs of pharmaceutical industries. In this period of economic crunch, pharmaceutical companies have indicated an increased interest in moving South and East of Europe, to tap into relatively low production and operational costs.

Frost & Sullivan is in the process of completing a Snapshot Study on Water & Wastewater Treatment in the European Pharmaceutical Industry. In the meantime, if you are interested in receiving more information on the European Water & Wastewater Treatment Markets, please send an e-mail to Chiara Carella - Corporate Communications at chiara.carella@frost.com with your full name, company name, title, telephone number, e-mail address, city and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

    Contacts:
    Chiara Carella
    Corporate Communications - Europe
    P: +44 (0) 20 7343 8314
    E: chiara.carella@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
2. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
3. Memory Pharmaceuticals Receives NASDAQ Decisions
4. MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference
5. Best Practice Database Adds Research Highlighting Effective Tactics of Sales Force and Manufacturing Groups in the Pharmaceutical Industry
6. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
7. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
8. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
9. China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
10. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
11. Idenix Pharmaceuticals to Present at the PiperJaffray 20th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... ... EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference ... estimated 5000 perioperative nurses in attendance to study the latest evidence-based recommendations ...
(Date:2/6/2016)... ... ... Shark Finds and Kevin Harrington, along with the Product Managers ... Belly Bands. , Having a dog is great—except when it wets every couch, bed, ... works, get Belly Bands, the easiest way to stop dogs from wetting on ...
(Date:2/5/2016)... NY (PRWEB) , ... February 05, 2016 , ... Love ... long-stem roses in a variety of colors, assortments and packaging. This staple for Valentine’s ... any King Kullen location. , For Valentine’s Day, not only are long-stem roses ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, MD and ... their Napa Valley office. The technique utilizes the body’s own healing abilities to ... Dr. Furnas, are part of only a select few cosmetic surgeons bringing this ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016   Bernstein Liebhard LLP ... filed in the United States District Court for the District ... class (the "Class") consisting of all persons or entities who ... "Company") (NASDAQ: INSY ) from March 3, 2015 through ... and certain of its officers with violations of the Securities ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
Breaking Medicine Technology: